



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	10/030,203
Filing Date	December 31, 2001
First Named Inventor	Alan Garen
Group Art Unit	1642
Examiner Name	TBD
Attorney Docket Number	006337.00004

TECH CENTER 1600/2900  
JUL 01 2003

RECEIVED

### U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
DB		4,752,569	06-21-1988	Terasaki et al.	
		4,865,998	09-12-1989	Feickert et al.	
		4,997,762	03-05-1991	Hanna, Jr. et al.	
		5,091,513	02-25-1992	Huston et al.	
		5,759,808	06-02-1998	Casterman et al.	
		5,800,988	09-01-1998	Casterman et al.	
		5,840,526	11-24-1998	Casterman et al.	
		5,939,530	08-17-1999	Gelboin et al.	
		5,969,107	10-19-1999	Carceller et al.	
		6,005,079	12-21-1999	Casterman et al.	
		6,015,695	01-18-2000	Casterman et al.	
		6,017,514	01-25-2000	Epstein et al.	
		6,140,470	10-31-2000	Garen et al.	
		6,555,319	04-29-2003	Wong, et al.	

### FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
DB		WO 90/14430	11-29-1990			
		WO 94/26787	11-24-1994			

Examiner  
Signature

*Sam Bluh*

Date  
Considered


5/6/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

**Complete if Known**

Application Number	10/030,203
Filing Date	December 31, 2001
First Named Inventor	Alan Garen
Group Art Unit	1642
Examiner Name	TBD
Attorney Docket Number	006337.00004

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DB		E. WILMES et al., "Versuche zur Herstellung menschlicher monoklonaler Antikörper gegen Melanome unter Verwendung zervikaler Lymphknoten," <u>Laryng. Rhinol. Otol.</u> , (1987), Vol. 68, pp. 144-148.	
		JAMIE K. SCOTT and GEORGE SMITH, "Searching for Peptide Ligands with an Epitope Library," <u>Science</u> , (July 27, 1990), Vol. 249, pp. 386-390.	
		JAMES D. MARKS et al., "By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage," <u>J. Med. Biol.</u> , (1991), Vol. 222, pp. 581-597.	
		GREG WINTER and CESAR MILSTEIN, "Man-made Antibodies," <u>Nature</u> , (January 24, 1991), Vol. 349, pp. 293-299.	
		JAMES D. MARKS et al., By-passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling," <u>BioTechnology</u> , (July 1992), Vol. 10, pp. 779-783.	
		G. DEL BINO et al., "Apoptotic Cell Death Triggered by Camptothecin or Teniposide. The Cell Cycle Specificity and Effects of Ionizing Radiation," <u>Cell Prolif.</u> , (1992), Vol. 25, pp. 537-548.	
		ANDREW D. GRIFFITHS et al., "Human Anti-self Antibodies with High Specificity from Phage Display Libraries," <u>The EMBO Journal</u> , (1993), Vol. 12, No. 2, pp. 725-734.	
		LEE H. PAI and IRA PASTAN, "Immunotoxin Therapy for Cancer," <u>JAMA</u> , (January 6, 1993), Vol. 269, No. 1, pp. 78-81.	
		DAVE S.B. HOON et al., "Molecular Cloning of a Human Monoclonal Antibody Reactive to Ganglioside Antigen on Human Cancers," <u>Cancer Research</u> , (November 1, 1993), Vol. 53, pp. 5244-5250.	
		MARIA-ANA GHETIE and ELLEN S. VITETTA, "Recent Developments in Immunotoxin Therapy," <u>Current Opinion in Immunology</u> , (1994), Vol. 6, pp. 707-714.	
		BRENDA L. HALL et al., "Establishment, Molecular Rescue, and Expression of 123AV16-1, a Tumor-reactive Human Monoclonal Antibody," <u>Cancer Research</u> , (1994), Vol. 54, pp. 5178-5185.	
		XIAOHONG CAI and ALAN GAREN, "Anti-melanoma Antibodies from Melanoma Patients Immunized with Genetically Modified Autologous tumor cells: Selection of Specific Antibodies from Single-Chain Fv Phage Fusion Libraries," <u>Proc. Natl. Acad. Sci. USA</u> , (1995), Vol. 92, pp. 6537-6541.	
		MARTIN FRIEDLANDER et al., "Involvement of Integrins $\alpha_3\beta_1$ and $\alpha_5\beta_1$ in Ocular Neovascular Diseases," <u>Proc. Natl. Acad. Sci. USA</u> , (September, 1996), Vol. 93, pp. 9764-9769.	
DB		XIAOHONG CAI and ALAN GAREN, "A Melanoma-Specific V <sub>H</sub> Antibody Cloned from a Fusion Phage Library of a Vaccinated Melanoma Patient," <u>Proc. Natl. Acad. Sci. USA</u> , (June 1996), Vol. 93, pp. 6280-6285.	

Examiner  
SignatureDate  
Considered

5/6/04

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B(10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		<b>C mplete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/030,203		
		Filing Date	December 31, 2001		
		First Named Inventor	Alan Garen		
		Group Art Unit	1642		
		Examiner Name	TBD		
Sheet	3	of	3	Attorney Docket Number	006337.00004


OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DB		CRAIG D. DICKINSON, "Identification of Surface Residues Mediating Tissue Factor Binding and Catalytic Function of the Serine Protease Factor VIIa", Proc. Natl. Acad. Sci USA, (December 1996), Vol. 93, pp. 14379-14384.	
		XIAOHONG CAI and ALAN GAREN, "Comparison of Fusion Phage Libraries Displaying V <sub>H</sub> or Single-chain Fv Antibody Fragments Derived from the Antibody Repertoire of a Vaccinated Melanoma Patient as a Source of Melanoma-Specific Targeting Molecules," Proc. Natl. Acad. Sci. USA, (August 1997), Vol. 94, pp. 9261-9266.	
		HENNIE R. HOOGENBOOM, "Designing and Optimizing Library Selection Strategies for Generating High-affinity Antibodies," <u>Tibtech</u> , (February 1997), Vol. 15, pp. 62-70.	
		BAIYANG WANG, et al, "Human Single-chain Fv Immunoconjugates Targeted to a Melanoma-associated Chondroitin Sulfate Proteoglycan Mediate Specific Lysis of Human Melanoma Cells by Natural Killer Cells and Complement," Proc. Natl. Acad. Sci. USA, (February 1999), Vol. 96, pp. 1627-1632.	
		DJ CHAPLIN and GJ DOUGHERTY, "Tumour Vasculature as a Target for Cancer Therapy," <u>British Journal of Cancer</u> , (1999), Vol. 80 (Supplement 1), pp. 57-64.	
		ZOLTAN SZEKANECZ et al., "Angiogenesis in Rheumatoid Arthritis: Pathogenic and Clinical Significance," <u>J Investig. Med.</u> , (1998), Vol. 46, pp. 27-41.	
		GARY S. FIRESTEIN, "Starving the Synovium: Angiogenesis and Inflammation in Rheumatoid Arthritis," <u>The Journal of Clinical Investigation</u> , (January 1999), Vol. 103, Number 1, pp. 3-4.	
		CHRIS M. STORGARD et al., "Decreased Angiogenesis and Arthritic Disease in Rabbits Treated with an $\alpha v\beta_3$ Antagonist," <u>The Journal of Clinical Investigation</u> , (1999), Vol. 103, Number 1, pp. 47-54.	
		HENRY J. KAPLAN et al., "Fas Ligand (CD95 Ligand) Controls Angiogenesis Beneath the Retina," <u>Nature Medicine</u> , (March 1999), Vol. 5, Number 3, pp. 292-297.	
		GLENN DRANOFF and RICHARD C. MULLIGAN, "Gene Transfer as Cancer Therapy," <u>Advances in Immunology</u> , Vol. 58, (1995), pp. 417-454.	
		E. HABER and F.F. RICHARDS, "The Specificity of Antigenic Recognition of Antibody Heavy Chain," Proc. R. Soc. Lond. B. Biol. Sci., (1996), Vol. 166, pp. 176-187.	
		ZHIWEI HU and ALAN GAREN, "Intratumoral Injection of Adenoviral Vectors Encoding Tumor-targeted Immunoconjugates for Cancer Immunotherapy," <u>Proc. Natl. Acad. Sci.</u> , (August 1, 2000), Vol. 97, No. 16, pp. 9221-9225.	
		ZHIWEI HU, et al, "Targeting Tissue Factor on Tumor Vascular Endothelial Cells and Tumor Cells for Immunotherapy in Mouse Models of Prostatic Cancer", <u>Proc. Natl. Acad. Sci.</u> , (October 9, 2001), Vol. 98, No. 21, pp. 12180-12185.	
DB		PURAN S. BORA, et al., "Immunotherapy for Choroidal Neovascularization of a Laser-induced Mouse Model Simulating Exudative (wet) Macular Degeneration," <u>Proc. Natl. Acad. Sci.</u> , Proc. Natl. Acad. Sci. USA, (March 4, 2003), Vol. 100, No. 5, pp. 2579-2684.	

Examiner Signature		Date Considered	5/6/04
-----------------------	--	--------------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Substitute for form 1449A/PTO Supplementary  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

**Complete If Known**

<b>Application Number</b>	10/030,203
<b>Filing Date</b>	12/31/2001
<b>First Named Inventor</b>	A. Garen
<b>Art Unit</b>	1642
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	OCR-679B.US (1368)

Sheet	1	of	1
-------	---	----	---


[illegible][illegible]

5/6/04

compliance and not considered. Include copy of this form with next communication to Applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**




Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete If Known</b>	
Application Number				10/030,203	
Filing Date				12/31/2001	
First Named Inventor				Alan Garen	
Art Unit				1642	
Examiner Name					
Attorney Docket Number				OCR-679B.US	
Sheet	1	of	2		

[illegible][illegible]

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED  
APR 03 2002



APR 01 2017

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet	2	of	2
-------	---	----	---

**Complete if Known**

Application Number	10/030,203
Filing Date	12/31/2001
First Named Inventor	Alan Garen
Group Art Unit	1642
Examiner Name	
Attorney Docket Number	OCR-679B.US

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

[illegible]

**Examiner  
Signature**

Frank Blakel

Date \_\_\_\_\_


**Considered**

5/6/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for Form 1449A/PTO</b> <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete If Known</b>	
		Application Number	10/030,203
		Filing Date	December 31, 2001
		First Named Inventor	Alan Garen
		Group Art Unit	1642
		Examiner Name	TBA
Sheet 1 of 1	Attorney Docket Number	006337.00004	

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
DB		5,605,690	02/25/1997	Jacobs et al.	
DB		6,140,470	10/31/2000	Garen et al.	
DB		6,448,071	09/10/2002	Schneck et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DB		DAL PORTO et al., "A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations", <i>Proc. Natl. Acad. Sci. USA</i> , July 1993, pp. 6671-6675, Vol. 90.	
		EILAT et al., "Secretion of a soluble, chimeric $\gamma\delta$ T-cell receptor-immunoglobulin heterodimer", <i>Proc. Natl. Acad. Sci. USA</i> , August 1992, pp. 6871-6875, Vol. 89.	
		GRÉGOIRE et al., "Engineered secreted T-cell receptor $\alpha\beta$ heterodimers", <i>Proc. Natl. Acad. Sci. USA</i> , September 1991, pp. 8077-8081, Vol. 88.	
		MOHLER et al., "Soluble Tumor Necrosis Factor (TNF) Receptors Are Effective Therapeutic Agents in Lethal Endotoxemia and Function Simultaneously as Both TNF Carriers and TNF Antagonists", <i>J. Immunol.</i> , August 1993, pp. 1548-1561, Vol. 151, No. 3.	
		ERBEN et al., "Differential effects of a stem cell factor-immunoglobulin fusion protein on malignant and normal hematopoietic cells", <i>Cancer Res.</i> , June 1999, pp. 2924-30, Vol. 59, No. 12 (Abstract only).	
		BABA, E., "Effects of IgC-Fc-mitomycin C conjugate on cancer cells", <i>Hokkaido Igaku Zasshi</i> , March 1996, pp. 271-81, Vol. 71, No. 2 (Article in Japanese; abstract only)	
DB		PEPPEL et al., "A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity", <i>J. Exp. Med.</i> , December 1991, pp. 1483-9, Vol. 174, No. 6. (Abstract only).	

Examiner Signature	<i>Tamara Blohm</i>	Date Considered	5/6/04
--------------------	---------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231